{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:34:18Z","timestamp":1789205658347,"version":"build-2803163510"},"reference-count":34,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["LHGJ20230240"],"award-info":[{"award-number":["LHGJ20230240"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,12,21]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a malignant plasma cell disorder. The most widely accepted staging system for MM is the revised International Staging System based on cytogenetic and clinical biomarkers. The circulating clonal plasma cells (CPCs) were reported to have potential prognostic impact on MM. Among various diagnostic approaches, multiparametric flow cytometry (FCM) offers heightened sensitivity, minimal invasiveness and reproducibility. We conducted a meta-analysis to evaluate the prognostic value of quantifying CPCs via FCM in newly diagnosed symptomatic MM (NDMM) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data source<\/jats:title>\n                    <jats:p>PubMed, Web of Science, Embase and references of included studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                    <jats:p>We included observational studies that evaluated the prognostic value of CPCs detected by FCM in NDMM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Data were screened and extracted independently by two investigators. The pooled results originated from random effects models. The primary endpoint was overall survival (OS). The secondary endpoint was progression-free survival (PFS). To evaluate the prognostic value of CPCs in NDMM, HRs and their 95% CI for both OS and PFS were derived using COX multivariable models. These values were then used to compute the pooled estimated effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our meta-analysis encompassed a total of 2704 NDMM patients from 11 studies up to 27 August 2022. The pooled HR for OS and PFS in CPC-positive (CPCs+) group and CPC-negative group were 1.95 (95% CI 1.24 to 3.07) and 2.07 (95% CI 1.79 to 2.39), respectively. The autologous stem cell transplantation (ASCT) failed to eliminate the adverse impact on OS and PFS. The heterogeneity may stem from the use of novel agents or traditional chemotherapy as initial treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis indicates CPCs+ had\u2009an adverse impact on the prognosis of NDMM patients in the total population, and the adverse impact could not be eliminated by ASCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42021272381.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-071548","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T12:35:23Z","timestamp":1705062923000},"page":"e071548","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"14","author":[{"given":"Xiaoyan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jili","family":"Deng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silin","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5582-5398","authenticated-orcid":false,"given":"Jie","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"2025121602320206000_14.1.e071548.1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"2025121602320206000_14.1.e071548.2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"2025121602320206000_14.1.e071548.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"2025121602320206000_14.1.e071548.4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/10428199409049709","article-title":"Significance of circulating plasma cells in multiple myeloma","volume":"14","author":"Zandecki","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"2025121602320206000_14.1.e071548.5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930701)72:1<108::AID-CNCR2820720121>3.0.CO;2-T"},{"key":"2025121602320206000_14.1.e071548.6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3286.3286","article-title":"Next-generation sequencing based minimal residual disease assessment in peripheral blood RNA from multiple myeloma patients","volume":"128","author":"Wolf","year":"2016","journal-title":"Blood"},{"key":"2025121602320206000_14.1.e071548.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04908.x"},{"key":"2025121602320206000_14.1.e071548.8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","author":"Gonsalves","year":"2017","journal-title":"Leukemia"},{"key":"2025121602320206000_14.1.e071548.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1858"},{"key":"2025121602320206000_14.1.e071548.10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13067"},{"key":"2025121602320206000_14.1.e071548.11","doi-asserted-by":"crossref","first-page":"2634853521999389","DOI":"10.1177\/2634853521999389","article-title":"Management of primary plasma cell leukemia remains challenging even in the era of novel agents","volume":"14","author":"Chaulagain","year":"2021","journal-title":"Clin Med Insights Blood Disord"},{"key":"2025121602320206000_14.1.e071548.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025121602320206000_14.1.e071548.13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.158303"},{"key":"2025121602320206000_14.1.e071548.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a mayo clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"key":"2025121602320206000_14.1.e071548.15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More than 2% of circulating tumor plasma cells defines plasma cell leukemia\u2013like multiple myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"JCO"},{"key":"2025121602320206000_14.1.e071548.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181447","article-title":"Prognostic value of circulating plasma cells in patients with multiple myeloma: a meta-analysis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS ONE"},{"key":"2025121602320206000_14.1.e071548.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2025121602320206000_14.1.e071548.18","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2025121602320206000_14.1.e071548.19","unstructured":"Wells GA , Shea B , O\u2019Connell D , et al . The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021. Available: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2025121602320206000_14.1.e071548.20","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2025121602320206000_14.1.e071548.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025121602320206000_14.1.e071548.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025121602320206000_14.1.e071548.23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/16078454.2021.1948208","article-title":"Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma","volume":"26","author":"Han","year":"2021","journal-title":"Hematology"},{"key":"2025121602320206000_14.1.e071548.24","doi-asserted-by":"crossref","first-page":"639528","DOI":"10.3389\/fonc.2021.639528","article-title":"Circulating plasma cells as a biomarker to predict newly diagnosed multiple myeloma prognosis: developing nomogram prognostic models","volume":"11","author":"Cheng","year":"2021","journal-title":"Front Oncol"},{"key":"2025121602320206000_14.1.e071548.25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17118","article-title":"The detection of circulating plasma cells may improve the revised international staging system (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma","volume":"193","author":"Galieni","year":"2021","journal-title":"Br J Haematol"},{"key":"2025121602320206000_14.1.e071548.26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cyto.b.21606","article-title":"Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma","volume":"94","author":"Bae","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"2025121602320206000_14.1.e071548.27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.13484","article-title":"Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics","volume":"170","author":"Vagnoni","year":"2015","journal-title":"Br J Haematol"},{"key":"2025121602320206000_14.1.e071548.28","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025121602320206000_14.1.e071548.29","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"JCO"},{"key":"2025121602320206000_14.1.e071548.30","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","article-title":"Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy","volume":"24","author":"Cowan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025121602320206000_14.1.e071548.31","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016","journal-title":"Blood Cancer J"},{"key":"2025121602320206000_14.1.e071548.32","first-page":"2736","article-title":"Blood-based risk stratification for pre-malignant and symptomatic plasma cell Neoplasms to improve patient management","volume":"11","author":"Vasco-Mogorr\u00f3n","year":"2021","journal-title":"American Journal of Cancer Research"},{"key":"2025121602320206000_14.1.e071548.33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cyto.b.21401","article-title":"Polychromatic flow cytometry is more sensitive than microscopy in detecting small monoclonal plasma cell populations","volume":"92","author":"Tran","year":"2017","journal-title":"Cytometry B Clin Cytom"},{"key":"2025121602320206000_14.1.e071548.34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2815.2815","article-title":"Elevated Cyclin D1 (Ccnd1) expression in the plasma cells of patients with systemic al amyloidosis at diagnosis is associated with higher brain natriuretic peptide (BNP) levels, increased plasma cells and significantly poorer survival","volume":"114","author":"Zhou","year":"2009","journal-title":"Blood"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-071548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:32:10Z","timestamp":1765881130000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-071548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,12]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjopen-2022-071548"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-071548","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}